A new clinical trial update was posted on August 14, 2026, for enicepatide, also known as RO7795068, a compound related to glucagon. The study, registered as NCT07351045, is titled "A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes."
The trial is listed as Phase 3 and its current status is recruiting. According to the registry entry, the study focuses on participants who have obesity or are overweight and who do not have type 2 diabetes.
No outcomes, results, or efficacy data have been reported for this trial at this stage. The listing reflects only the trial's design, phase, and recruitment status as of the date given. No safety or benefit conclusions can be drawn from a recruiting status alone.
Additional details about the trial, including its full protocol and eligibility criteria, are available through the official clinical trial registry listing linked with this update.
Readers interested in background on this compound can consult the compound overview for further context.